T A B L E O F C O N T E N
hospitalisations, episodes of pneumonia or adverse events. The results on exacerbations were heterogeneous and were not combined. The mean health-related quality of life and lung function were significantly different when combination therapy was added to tiotropium, although the size of the average benefits of additional combination therapy were small, St George's Respiratory Questionnaire (MD -2.49; 95% CI -4.04 to -0.94) and forced expiratory volume in one second (MD 0.06 L; 95% CI 0.04 to 0.08).
One trial (60 patients) compared tiotropium plus combination therapy to combination therapy alone. The results from the trial were insufficient to draw firm conclusions for this comparison.
Authors' conclusions
To date there is uncertainty regarding the long-term benefits and risks of treatment with tiotropium in addition to inhaled corticosteroid and long-acting beta 2 -agonist combination therapy on mortality, hospitalisation, exacerbations of COPD and pneumonia. The addition of combination treatment to tiotropium has shown improvements in average health-related quality of life and lung function.
P L A I N L A N G U A G E S U M M A R Y
Is it better to take tiotropium plus combination inhalers than tiotropium or combination inhalers alone for the treatment of chronic obstructive pulmonary disease?
Chronic obstructive pulmonary disease (COPD) is a lung disease which includes the conditions chronic bronchitis and/or emphysema. COPD is characterised by blockage or narrowing of the airways. The symptoms include breathlessness and chronic cough. COPD is an irreversible disease that is usually brought on by airway irritants, such as smoking or inhaled dust.
Inhalers with bronchodilators and/or anti-inflammatory agents are commonly used to ease symptoms and minimise the long-term decline in health caused by COPD. Examples of these treatments are tiotropium which is a bronchodilator and combination inhalers which contain another type of bronchodilator (long-acting beta-agonists) together with anti-inflammatory agents (steroids). These treatments work in different ways and therefore might be more beneficial if used together.
This review found three studies, involving 1021 patients, comparing the long-term efficacy and side effects of combining tiotropium with combination inhalers for treating COPD. In these studies there were not enough patients and the studies were too different from each other for us to be able to draw any firm conclusions as to whether combining tiotropium with combination inhalers is better or worse than using either drug alone for mortality, hospitalisation and pneumonia. The addition of combination inhalers to tiotropium did show small benefits in quality of life and lung function tests.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Tiotropium plus LABA/ICS combination compared to Tiotropium plus placebo for chronic obstructive pulmonary disease *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; OR: odds ratio;
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.
B A C K G R O U N D

Description of the condition
Chronic obstructive pulmonary disease (COPD) is a general term referring to chronic bronchitis and emphysema, or both. COPD occurs when airflow to the lungs is restricted because of narrowing of the airways. Symptoms include cough, breathlessness and reduced exercise capacity. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines describe COPD as a preventable and treatable condition that is not fully reversible. Worldwide, the main cause of COPD is tobacco smoking, however air pollution is also a risk factor. The prevalence, morbidity and mortality of the disease vary across populations and cause a substantial economic and social burden.
There are a number of commonly used pharmacological treatments in COPD management that are used to relieve symptoms, improve exercise tolerance and quality of life, reduce mortality, and prevent and treat exacerbations. COPD exacerbations impair patients' quality of life and a large part of the economic burden of COPD is attributed to the cost of managing exacerbations, particularly those resulting in use of acute care services or hospitalisations (Hutchinson 2010). Appropriate pharmacological management of the disease is therefore important to reduce and prevent exacerbations. COPD management tends to begin with one treatment and additional therapies are introduced as necessary to control symptoms (GOLD). Self-management education and rehabilitation can accompany these pharmacological interventions (Effing 2007; Lacasse 2006) .
Description of the intervention
The first pharmacological step in treating COPD is the use of short-acting bronchodilators for symptom control when needed. These include short-acting beta 2 -agonists (SABA) and the shortacting anticholinergic ipratropium. For managing persistent COPD symptoms, long-acting bronchodilators can be introduced (GOLD). Regular treatment with long-acting bronchodilators is both more efficient and convenient than treatment with regular short-acting bronchodilators (Beeh 2010). Long-acting bronchodilators include long-acting beta 2 -agonists (LABA) and the long-acting anticholinergic agent tiotropium. Tiotropium bromide has gained widespread acceptance as a once daily maintenance therapy in COPD (Barr 2005; GOLD) . Tiotropium reduces COPD exacerbations and related hospitalisations compared to ipratropium (Barr 2005) . Most long-acting beta 2 -agonists are taken twice daily. They improve lung function compared to ipratropium, but there is little difference in improving COPD symptoms and exercise tolerance (Appleton 2006) . For symptomatic patients with severe or very severe COPD (FEV 1 < 50% predicted) and with repeated exacerbations, GOLD recommends the addition of inhaled corticosteroids (ICS) to bronchodilator treatment. Inhaled corticosteroids are licensed as combination inhalers with long-acting beta 2 -agonists. The most common combinations of inhaled corticosteroid and long-acting beta 2 -agonist in combination inhalers are fluticasone and salmeterol and budesonide and formoterol. Combination therapy reduces exacerbation rates and all-cause mortality compared to inhaled corticosteroid alone (Nannini 2007) . Also compared to long-acting beta 2 -agonists alone, combination therapy is more effective in reducing exacerbation rates, but there is no significant difference in mortality (Nannini 2007b). The benefits of combination inhalers should be viewed against the possible increased risk of pneumonia (Nannini 2007b). The potential risks or benefits of treatment with combination inhaler compared to tiotropium are uncertain (Welsh 2010), as are the risks or benefits of treatment with combination inhaler in addition to tiotropium, which will be explored in this review.
How the intervention might work Tiotropium
Tiotropium is a long-acting anticholinergic agent that targets bronchospasm in COPD by relaxing airway smooth muscle. Tiotropium is structurally related to ipratropium, a short-acting anticholinergic agent that binds to M1, M2 and M3 muscarinic receptors which in turn open the bronchi (Barr 2005). Although tiotropium binds to the same receptors as ipratropium, it has a different kinetic selectivity. Tiotropium dissociates slowly from M1 and M3 receptors giving a bronchodilator effect lasting over 24 hours, but rapidly from M2 receptors. It appears that M2 receptors are feedback inhibitory receptors, and blocking them (as is the case for ipratropium) releases acetylcholine rather than reducing it as desired (Barr 2005) . Benefits of tiotropium, in comparison with placebo, include reduced COPD exacerbations and exacerbationrelated hospitalisations, and improved health-related quality of life and symptom scores among patients with moderate and severe disease (Barr 2005) . Anticholinergic side effects can occur with tiotropium and include dry mouth, constipation and tachycardia.
Combination inhalers
Inhaled beta 2 -agonists activate beta 2 -receptors in the smooth muscle of the airway, releasing adenylate cyclase and increasing intracellular cAMP (cyclic adenosine monophosphate) which leads to a cascade of reactions resulting in bronchodilation. Beta 2 -agonists may act through other mechanisms such as respiratory muscle function or mucociliary clearance, because patients have shown improvement in symptoms whilst showing no improvement in lung function tests. Beta 2 -agonists are particularly useful because they reverse bronchoconstriction regardless of the initial cause of the bronchoconstriction. Side effects include muscle tremors, nervousness and occasional insomnia but, as with all inhaled medications, systemic side effects are minimised by giving a comparatively low dose directly to the lungs. Inhaled corticosteroids are anti-inflammatory drugs. They reduce the rate of exacerbations and the rate of decline in quality of life compared to placebo, without effect on overall mortality or the long-term decline in FEV 1 (GOLD; Yang 2007). Combination inhalers including inhaled corticosteroids and long-acting beta 2 -agonists reduce exacerbation rates and all-cause mortality, and improve lung function and quality of life compared to placebo (Nannini 2007a). These effects are thought to be greater for combination inhalers than from the component preparations (GOLD). Inhaled corticosteroids, alone or in combination with beta 2 -agonists, potentially increase the risk of pneumonia (GOLD; Yang 2007).
Why it is important to do this review
Although both tiotropium and combination therapy inhalers are recommended for treatment of COPD, the relative effects of combination therapy compared to tiotropium on patients with COPD are unclear (Welsh 2010). However, it has been hypothesised that combining bronchodilators with different mechanisms and duration of action may be more effective than the individual components in improving bronchodilation without increasing side effects. For example a combination of salbutamol and ipratropium has been shown to improve FEV 1 without an associated increase in tachyphylaxis (GOLD). Recent trials have been published on adding tiotropium to combined inhalers, and this review is necessary to show whether there is a benefit from this treatment regime compared to tiotropium or combination therapy alone.
O B J E C T I V E S
To assess the relative effects of the following treatments on markers of exacerbations, symptoms, quality of life, and lung function in patients with COPD:
• Tiotropium plus LABA/ICS versus tiotropium
• Tiotropium plus LABA/ICS versus LABA/ICS
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials with a parallel group design of at least three months' duration. Studies were not excluded on the basis of blinding.
Types of participants
Populations with a diagnosis of COPD. We included only studies that used an external set of criteria to screen participants for this condition (e.g. GOLD; ATS; BTS; TSANZ). 
Types of interventions
Search methods for identification of studies Electronic searches
We identified trials using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and PsycINFO, and handsearching of respiratory journals and meeting abstracts (please see the Airways Group Module for further details). All records in the Specialised Register coded as 'COPD' were searched using the following terms: (tiotropium or spiriva) AND (((budesonide or fluticasone or beclomethasone or mometasone or steroid* or corticosteroid*) and (*formoterol or salmeterol or indacterol or (beta* and agonist*))) or (symbicort or viani or seretide or advair or foster or fostair or inuvair or fostex or kantos or combination*)) The search was conducted in July 2010.
Searching other resources
We reviewed reference lists of all primary studies and review articles for additional references. We contacted authors of identified trials and we asked them to identify other published or unpublished studies.
Data collection and analysis
Selection of studies
Two review authors (CK and CJC) screened the titles and abstracts of citations retrieved through literature searches and obtained those deemed to be potentially relevant. Each reference was assigned to a study identifier and assessed against the inclusion criteria of this protocol.
Data extraction and management
We extracted information from each study for the following characteristics:
1. Design (design, total duration study and run in, number of study centres and location, withdrawals, date of study).
2. Participants (N, mean age, age range, gender, COPD severity, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, exclusion criteria).
3. Interventions (run-in, intervention treatment and inhaler type, control treatment and inhaler type).
4. Outcomes (primary and secondary outcomes specified and collected, time points reported). Two authors (CK and CJC) extracted data from the studies into data collection forms. Any discrepancies in the data were discussed and resolved between the authors. The data were then transferred from data collection forms into Review Manager 5.
Assessment of risk of bias in included studies
We assessed all included studies for the risk of bias according to recommendations outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2009) for the following items:
1. Allocation sequence generation 2. Concealment of allocation 3. Blinding of participants and investigators 4. Incomplete outcome data 5. Selective outcome reporting Other sources of bias have been noted. We graded each potential source of bias as yes, no or unclear, relating to whether the potential for bias was low, high or unknown respectively.
Measures of treatment effect
We analysed dichotomous variables (such as mortality, participants with at least one hospital admission etc.) using the Mantel-Haenszel fixed odds ratio with 95% confidence intervals, unless events were rare, in which case we employed the Peto odds ratio (since this does not require a continuity correction for zero cells). We analysed continuous outcome data (such as quality of life and FEV 1 ) as fixed-effect mean differences with 95% confidence intervals as the same scale was used. Where treatment effects were reported as a mean difference with 95% confidence intervals, we entered the mean difference and standard errors calculated from 95% confidence intervals and analysed the data using the generic inverse variance (GIV) tool in Review Manager 5. For data which were not reported as the number of participants experiencing an event, we entered the natural log of reported rate ratios along with the standard error calculated from 95% confidence intervals into Review Manager 5 using the GIV function.
Unit of analysis issues
We analysed dichotomous data using participants as the unit of analysis (rather than events) to avoid counting the same participant more than once.
Dealing with missing data
We contacted investigators and study sponsors in order to verify key study characteristics and obtain missing numerical outcome data.
Assessment of heterogeneity
We assessed the amount of statistical variation between the study results with the I 2 measurement.
Assessment of reporting biases
We minimised reporting bias from non-publication of studies or selective outcome reporting by using a broad search strategy, contacting study authors directly and checking references of included studies. We planned to assess reporting bias by visual inspection of funnel plots.
Data synthesis
We combined dichotomous data using Mantel-Haenszel odds ratios with a fixed-effect model and compared this to the randomeffects model. We combined rate ratios and hazard ratios using generic inverse variance using a fixed-effect model and compared to the random-effects model. We planned to calculate the numbers needed to treat for an additional beneficial outcome from the pooled odds ratio and its confidence interval, and apply to appropriate levels of baseline risk. We have presented the findings of our primary outcomes in Summary of findings for the main comparison generated using GradePro software.
Subgroup analysis and investigation of heterogeneity
We planned to subgroup studies according to: 1. Type of combination therapy 2. Severity of disease at baseline
Sensitivity analysis
We intended to assess the sensitivity of our primary outcomes to degree of bias by comparing the overall results with those exclusively from trials assessed as being at low risk of bias.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of studies awaiting classification.
Results of the search
The initial search identified 101 references. Of these we identified 24 as potentially relevant, which we obtained in full text for further assessment. Fourteen of these were eligible for inclusion and belonged to three studies ( An assessment of the risk of bias is presented in the Characteristics of included studies table, and an overview of the findings is shown in Figure 1 . For both studies randomisation was computergenerated through central allocation and both research staff and patients were blinded to the treatment assignment until the end of study. Cazzola 2007 did not report full details regarding sequence generation and allocation concealment in the study report.
Blinding
The blinding in Aaron 2007 and Welte 2009 was adequate. Cazzola 2007 did not report full details of blinding procedures. In Aaron 2007, the different inhalers containing placebo, salmeterol, and fluticasone/salmeterol were identical in taste and appearance, and they were enclosed in identical tamper-proof blinding devices. The medication canisters within the blinding devices were stripped of any identifying labelling. Clinical data for suspected exacerbations were reviewed by a blinded committee judging whether the data met the study definition of COPD exacerbation. Blinding of patients was not broken for patients who prematurely discontinued treatment with study medications, and the statistician who performed the analysis was initially blinded to patient group assignments. In Welte 2009, treatment assignment was concealed as active and placebo inhalers were of identical appearance and both clinicians and patients were blinded to treatment until completion of the study.
Incomplete outcome data
Cazzola 2007 and Welte 2009 did not suffer from incomplete outcome data. Aaron 2007 suffered from high and uneven withdrawal rates in the different study groups (74 patients (47%) withdrew from the tiotropium + placebo group and 37 patients (26%) on tiotropium + LABA/ICS). High withdrawal rates are common in COPD trials over six months in length. For most patients, data were recorded throughout the one-year trial period regardless of whether patients discontinued treatment with study medications. The rate of patients who stopped therapy and did not complete the trial, however, was still relatively large and unevenly distributed between the intervention groups (30 patients (19%) tiotropium + placebo and 15 patients (10%) tiotropium + LABA/ICS). Mortality data were obtained for all participants with the exception of 2/145 (1.4%) on tiotropium + LABA/ICS and 4/ 156 (2.6%) on tiotropium + placebo who withdrew and declined further study.
Selective reporting
All three trials adequately reported outcome data for the primary and secondary outcomes that they had pre-specified in the study record.
Effects of interventions
See: Summary of findings for the main comparison Tiotropium plus LABA/ICS combination compared to Tiotropium plus placebo for chronic obstructive pulmonary disease Because of the low number of eligible studies for the two comparisons (tiotropium + LABA/ICS versus tiotropium alone or versus LABA/ICS alone), no subgroup analysis of disease severity or type of combination therapy were possible.
Tiotropium plus LABA/ICS versus tiotropium plus placebo
Two authors (CK and CJC) independently extracted and analysed results for all data. Dichotomous data including mortality, exacerbations, pneumonia, adverse events and withdrawals were analysed as end of study measurements as this was the only time point for which these data were available. Continuous data were analysed at three months for Cazzola 2007 and Welte 2009 (end of study) and at both five months (20 weeks) and one year for Aaron 2007.
Primary outcome: mortality (all causes)
Mortality data were available from two trials involving 1021 participants, which reported mortality as a secondary outcome (Aaron 2007; Welte 2009). The third study, Cazzola 2007 (60 participants), reported zero serious adverse events and therefore we assumed there were no mortalities during the study. Taken together, there was a greater number of deaths in the tiotropium + LABA/ ICS group (7/504) than in the tiotropium + placebo group (4/ 517), however, there was no statistically significant difference in mortality between the groups (Peto odds ratio (OR) 1.88; 95% confidence interval (CI) 0.57 to 6.23) as shown in Figure 2 . The number of withdrawals from each of the arms in Aaron 2007, which adds most weight to the comparison, was six times larger than the number of deaths for participants on tiotropium + LABA/ ICS and 19 times larger for participants on tiotropium + placebo. This uncertainty about the results is not reflected in the confidence interval for the odds ratio. Figure 4 ), although the difference was not statistically significant for the pooled result or the result from individual studies. In the three included studies (1021 patients) there were fewer patients suffering non-fatal serious adverse events in the tiotropium + LABA/ICS group (12/504) than in patients on tiotropium + placebo (20/517) (OR 0.60; 95% CI 0.29 to 1.25), although the difference was not statistically significant.
Secondary outcome: adverse events
In the three included studies (1021 patients) there was a slightly larger number of patients suffering adverse events on tiotropium + LABA/ICS (140/504) than on patients on tiotropium + placebo (132/517) (OR 1.12; 95% CI 0.85 to 1.49), again the difference was not statistically significant.
Secondary outcome: side effects
Side effects were not reported in any of the included studies.
Secondary outcome: withdrawal
All three studies (1021 patients) reported the withdrawals from the study. There were many withdrawals for any reason from the longer of the three studies (Aaron 2007) and in this study the withdrawal rate was significantly higher in the tiotropium + placebo group (47%) than in the tiotropium + LABA/ICS group (26%) (OR 0.38; 95% CI 0.23 to 0.62). The two shorter studies had fewer withdrawals and they were more evenly distributed between the tiotropium + LABA/ICS groups (Cazzola 2007, 3/13% and Welte 2009 8/9% in the tiotropium + LABA/ICS /tiotropium + placebo group respectively). Both Aaron 2007 and Welte 2009 reported the breakdown of the reasons for withdrawals, which showed that the difference between the number withdrawing due to adverse events (OR 0.92; 95% CI 0.46 to 1.83) was not statistically significant, whereas the difference between the number withdrawing due to lack of efficacy was significantly higher in the tiotropium + placebo group than in the tiotropium + LABA/ICS group (OR 0.36; 95% CI 0.22 to 0.59).
Tiotropium plus LABA/ICS versus LABA/ICS plus placebo
Cazzola 2007 was the only eligible study identified comparing tiotropium + LABA/ICS versus LABA/ICS + placebo (60 patients). The study reported results for the following outcomes of interest for this review:
Primary outcome: mortality (all causes)
Cazzola 2007 reported zero serious adverse events and therefore we assumed there were no deaths during the study. Tiotropium in combination with LABA/ICS improves FEV 1 significantly compared to LABA/ICS + placebo (MD 0.05; 95% CI 0.00 to 0.09), but the mean difference and confidence interval were below the minimal clinically important difference of 100 to140 mL.
Secondary outcome: serious adverse events (non-fatal)
There were no serious adverse events in either intervention group.
Secondary outcome: adverse events
There were more adverse events in the tiotropium + LABA/ICS group (15/30) than in the tiotropium + placebo group (8/30), but the confidence interval was wide, due to small numbers of events (OR 2.75; 95% CI 0.93 to 8.10).
Secondary outcome: withdrawal
There were fewer withdrawals in the tiotropium + LABA/ICS group (1/30) than the tiotropium + placebo group (4/30), but the number of events was small and not statistically significant (OR 0.22; 95% CI 0.02 to 2.14).
D I S C U S S I O N
Summary of main results
This systematic review set out to investigate the long-term (≥ three months) effects of tiotropium in combination with LABA/ICS compared to either LABA/ICS alone or tiotropium alone, for the treatment of COPD. Three randomised, double-blind, placebocontrolled trials with 1021 participants were identified. All three studied the effects of tiotropium in combination with LABA/ICS compared to tiotropium alone, whereas only one of these studies (60 participants) also looked at tiotropium in combination with LABA/ICS compared to LABA/ICS (Cazzola 2007).
Tiotropium plus LABA/ICS versus tiotropium plus placebo
The results from this review did not show any significant difference between tiotropium + LABA/ICS and tiotropium + placebo in mortality, the number of patients suffering from pneumonia, or having one or more hospital admissions. However, the individual study authors' analyses of rate ratios showed a significant benefit of tiotropium + LABA/ICS treatment compared to tiotropium alone for the total number of hospital admissions (Aaron 2007), and for exacerbations leading to hospitalisations or emergency room visits (Aaron 2007; Welte 2009). We did not pool data for number of patients suffering one or more exacerbations due to heterogeneity. This review did find that tiotropium in combination with LABA/ ICS significantly improved FEV 1 for COPD patients compared to treatment with tiotropium alone. However, the mean increase was below what may be considered a clinically significant difference (100 to 140 mL). Similarly mean change in quality of life scores was lower than a four unit change (which is considered to be clinically significant), although the change, favouring tiotropium + LABA/ ICS treatment, was statistically significant. One included study reported significantly more patients with a clinically significant improvement in their quality of life score in the tiotropium + LABA/ICS group than in the group on tiotropium alone (Welte 2009). The effect of tiotropium + LABA/ICS combination treatment on mortality and pneumonia remains uncertain due to the low numbers of events, which were small in comparison to the high numbers of withdrawals and participants lost to follow-up. Also, Aaron 2007 reported only pneumonia leading to mechanical ventilation or death as the study took place at a time when the authors were unaware of any association of pneumonia with the use of inhaled corticosteroids. Even though there was no significant difference in the number of patients admitted to hospital due to exacerbations or all causes, Aaron 2007 reported a significant difference in all cause hospitalisation (rate ratio 0.67; 95% CI 0.45 to 0.99) and hospital admissions due to exacerbation (rate ratio 0.53; 95% CI 0.33 to 0.86) when data were analysed as rate ratios. Similarly Welte 2009 reported significantly lower numbers of hospitalisations/ emergency room visits for exacerbations in the tiotropium + LABA/ICS group compared to the tiotropium + placebo group (rate ratio 0.35; 95% CI 0.16 to 0.78). There are many ways to analyse exacerbation/ hospitalisation rates and all have different advantages and disadvantages. Looking at the number of patients suffering one or more exacerbation will show the direction of the intervention effect but it does not give any information about potential difference in exacerbation frequency in the same patient and it does not take into account variable lengths of study time (Keene 2008) . Using the rate ratio of exacerbations is more informative about exacerbation rates in the trial populations, but the various different statistical methods used to calculate this means that one has to be careful when combining/pooling the results from different trials. There are many possible reasons for the discrepancies in statistical significance between the results when they are analysed in different ways. There may be a difference in power between the methods, and chance could lead to a significant difference using one method and a non-significant difference using another. Welte 2009 showed significantly fewer exacerbations in the group treated with tiotropium + LABA/ICS compared to the group treated with tiotropium + placebo (OR 0.38; 95% CI 0.25 to 0.57), whereas Aaron 2007 showed no significant difference between the two groups (OR 0.85; 95% CI 0.65 to 1.11). The difference between the study results was large enough to introduce considerable heterogeneity, and the two study results were therefore not combined. The reason for the heterogeneity is unknown but there are considerable differences between the two studies which could have an influence including; type of combination treatment, length of study, baseline risk, and notably definition of exacerbation. Aaron 2007 defined exacerbation as a worsening of COPD leading to treatment with systemic steroids and/or antibiotics. Welte 2009 defined exacerbation as a worsening of COPD leading to treatment with systemic steroids and/or hospitalisation/ emergency room visits. Treatment with tiotropium + LABA/ICS led to a greater improvement in health-related quality of life than treatment with tiotropium alone. However, the mean difference in quality of life score was below the limit of clinical significance (less than four units) although the difference between the intervention groups was statistically significant (MD -2.49; 95% CI -4.04 to -0.94). However, Welte 2009 showed a statistically significant difference in the number of patients who had a clinically significant improvement in quality of life score (tiotropium + LABA/ICS 49.5%, tiotropium + placebo 40.0%, P = 0.016), whereas there was no significant difference in the number whose quality of life score deteriorated (tiotropium + LABA/ICS 27.6%, tiotropium + placebo 29.7%). This illustrates that a small mean difference does not rule out the possibility of additional combination treatment being of benefit in some patients. This possibility does not only cover health-related quality of life but also changes in FEV 1 . The difference in serious adverse events between the intervention groups was not statistically significant. The numbers were low in total and compared to the number of withdrawals and participants lost to follow-up. The withdrawals from the studies did not seem to be linked to adverse events but to the efficacy of the treatment.
placebo
The one pilot study looking at the effect of LABA/ICS + tiotropium versus LABA/ICS + placebo showed a significantly larger improvement in FEV 1 with tiotropium + LABA/ICS treatment compared to LABA/ICS treatment (Cazzola 2007), however the mean difference in FEV 1 was not clinically significant. All other outcomes of interest were either not studied, had no events or did not achieve a statistically significant difference.
Overall completeness and applicability of evidence
For the comparison of the benefits and risks of treatment with tiotropium + LABA/ICS versus LABA/ICS one smaller study was eligible (Cazzola 2007), which did not look at or report any of the primary outcomes specified in this review except for mortality. Therefore there was little applicable evidence for this comparison from this review. For the comparison of the benefits and risks of treatment with tiotropium + LABA/ICS versus tiotropium, the total number of patients in the included studies was insufficient and the differences between the studies too many (type of combination treatment, study length, definition of outcomes) to show any relevant statistically significant difference for several of the outcomes. One limitation of the included studies was their duration. Two out of three studies (Cazzola 2007; Welte 2009) were only three months and the third was one year (Aaron 2007). A minimum of six months' treatment would be advisable to be able to judge longterm benefits and risks of the studied interventions. However such a criteria also limits the number of eligible studies and leads to larger numbers of withdrawals in the included studies, which in turn will lead to an increased risk of bias. There were too few eligible studies to break down the result in subgroups of disease severity or type of combination therapy.
Quality of the evidence
Aaron 2007 and Welte 2009 were of good methodological quality. However, long COPD trials (longer than six months) like Aaron 2007, which are essential to study long-term efficacy and risks with COPD interventions, will inevitably suffer from large numbers of withdrawals (Welsh 2010). Aaron 2007 did address this issue by sensitivity analyses for their primary outcome; COPD exacerbation. The authors assumed that all patients who were lost to follow-up in both intervention groups either did not have an exacerbation, had an exacerbation or had exacerbations at the same rate as those who continued in the study. However, they did not investigate the effect of the greatest possible difference between the intervention groups; assuming that all patients lost to followup in one intervention groups had an exacerbation and that all patients lost to follow-up in the other intervention group did not have an exacerbation. Even though the issue of withdrawals was addressed, it could introduce bias. Cazzola 2007 could not provide additional information regarding allocation concealment, blinding, funding and withdrawals and therefore introduced an unknown risk of bias. However, a sensitivity analysis removing the Cazzola 2007 data from the FEV 1 analysis did not change the outcome substantially.
Potential biases in the review process
The issue of large and/or uneven numbers of withdrawals, as mentioned above (Quality of the evidence), will, even if addressed, possibly introduce bias as there is no consensus on how to handle participants for whom no data are available. We analysed available data as specified in the protocol. However, we did expand the review question from the protocol to include the comparison of tiotropium + LABA/ICS versus LABA/ICS + placebo. We also highlighted rate ratios for hospital admissions and percentage of patients with a clinically significant change in health-related quality of life reported by the authors although this was not specified in Measures of treatment effect.
Agreements and disagreements with other studies or reviews
No reviews looking at the long-term efficacy and adverse effects of tiotropium + LABA/ICS treatment compared to tiotropium or LABA/ICS have been identified. However, a systematic review looking at LABA/ICS combination treatment compared to placebo has shown that combination treatment significantly reduces mortality and exacerbation rates, and improves lung function (Nannini 2007). LABA/ICS also increases the risk of pneumonia compared with placebo. Tiotropium on its own has been shown to reduce COPD exacerbations and related hospitalisations compared to placebo (Barr 2005) . Tiotropium also improves health-related quality of life among patients with moderate and severe disease. Although no conclusion has been drawn regarding the effect of tiotropium on mortality rates and change in FEV 1 (Barr 2005), these reviews may give an indication of the treatment efficacy that can be anticipated from treatment with tiotropium + LABA/ICS compared to tiotropium alone.
A U T H O R S ' C O N C L U S I O N S Implications for practice
The total patient number from the included studies was insufficient and the differences between the studies too great to draw any general conclusions from the results regarding the long-term effects and risks of tiotropium + LABA/ICS treatment. The relative
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aaron 2007
Methods
Design: A randomised, double-blind, placebo-controlled, parallel group trial from October 2003 to January 2006. The trial included 27 Canadian medical centres; 20 centres were academic hospital-based pulmonary clinics, 5 were community-based pulmonary clinics, and 2 were community-based primary care clinics Participants Population: 449 adults with a clinical history of moderate or severe COPD as defined by ATS and GOLD guidelines Baseline Characteristics: Mean age 68 years. COPD severity moderate to severe with mean FEV 1 predicted of 39%. 44% women. Inclusion Criteria: At least 1 exacerbation of COPD that required treatment with systemic steroids or antibiotics within the 12 months before randomisation; age older than 35 years; a history of 10 pack-years or more of cigarette smoking; documented chronic airflow obstruction, with an FEV 1 /FVC ratio less than 0.70 and a post-bronchodilator FEV 1 less than 65% of the predicted value. Exclusion Criteria: History of physician-diagnosed asthma before 40 years of age; history of physician-diagnosed chronic congestive heart failure with known persistent severe left ventricular dysfunction; those receiving oral prednisone; those with a known hypersensitivity or intolerance to tiotropium, salmeterol, or fluticasone-salmeterol; history of severe glaucoma or severe urinary tract obstruction, previous lung transplantation or lung volume reduction surgery, or diffuse bilateral bronchiectasis; and those who were pregnant or were breastfeeding Interventions 1. Tiotropium + salmeterol + fluticasone: tiotropium (Spiriva, Handihaler (Boehringer Ingelheim Pharma, Ingelheim, Germany)), 18 g once daily, plus fluticasone-salmeterol (Advair (GlaxoSmithKline)), 250/25 g/puff, 2 puffs twice daily 2. Tiotropium + salmeterol: tiotropium, 18 g once daily, plus salmeterol (Serevent (GlaxoSmithKline, Research Triangle Park, North Carolina)), 25 g/puff, 2 puffs twice daily 3. Tiotropium + placebo: tiotropium, 18g once daily, plus placebo inhaler, 2 puffs twice daily Outcomes Primary: Proportion of patients with one or more exacerbation of COPD Secondary: Mean number of COPD exacerbations per patient-year; the total number of exacerbations that resulted in urgent visits to a healthcare provider or emergency department; the number of hospitalisations for COPD; the total number of hospitalisations for all causes; changes in health-related quality of life, dyspnoea, lung function Notes Co-medication: All study patients were provided with inhaled albuterol and were instructed to use it when necessary to relieve symptoms. Any treatment with inhaled corticosteroids, long-acting 2-agonists, and anticholinergics that the patient may have been using before entry was discontinued on entry into the study. Therapy with other respiratory medications, such as oxygen, antileukotrienes, and methylxanthines, was continued in all patient groups
Aaron 2007 (Continued)
Item
Authors' judgement Description
Adequate sequence generation? Yes Randomisation was done through central allocation of a randomisation schedule that was prepared from a computer-generated random listing of the 3 treatment allocations, blocked in variable blocks of 9 or 12 and stratified by site Allocation concealment? Yes Neither research staff nor patients were aware of the treatment assignment before or after randomisation
Blinding? All outcomes
Yes
The metered-dose inhalers containing placebo, salmeterol, and fluticasone-salmeterol were identical in taste and appearance, and they were enclosed in identical tamper-proof blinding devices. The medication canisters within the blinding devices were stripped of any identifying labelling Incomplete outcome data addressed? All outcomes Unclear The number of people who stopped drug therapy was high, with large variations between the groups (74 (47%) tiotropium + placebo and 37 (26%) tiotropium + LABA/ICS comb.). However, the number of people who did not complete the trial was lower, although there was still large variations between the groups (30 (19%) tiotropium + placebo and 15 (10%) tiotropium + LABA/ICS comb.). The issue of incomplete data was however addressed by sensitivity analyses of the data comprising alternative assumptions for patients who prematurely withdrew from treatment Free of selective reporting? Yes Results for all listed primary and secondary outcomes were reported
Cazzola 2007
Methods Design: A randomised, double-blind, double-dummy, parallel group trial over 12 weeks Participants Population: 90 patients with well-controlled COPD. Baseline Characteristics: Mean age 66 years. COPD severity severe to very severe with mean FEV 1 predicted of 38%. 11% women. Inclusion Criteria: Baseline FEV 1 of less than 50% of predicted, and a post-bronchodilator FEV 1 /FVC < 70% following salbutamol 400 mg according to the GOLD
Welte 2009
Methods Design: A randomised, double-blind, parallel-group, multicenter trial from May 2007 to June 2008. The trial included 102 centres in 9 countries: Australia (10 centres), Canada (16), France (12), Germany (12), Hungary (13), Poland (10), Slovakia (13), Spain (6) and Sweden (10) Participants Population: 660 patients with COPD eligible for LABA/ICS combination therapy, with a pre-bronchodilator FEV 1 not exceeding 50% of the predicted normal value and a history of exacerbations requiring systemic steroids and/or antibiotics, were studied Baseline Characteristics: Mean age 62 years. COPD severity, moderate, severe to very severe with mean FEV 1 predicted of 38%. 25% women. Inclusion Criteria: Patients with COPD eligible for inhaled corticosteroid/long-acting beta 2 -agonist (LABA/ICS) combination therapy aged ≥ 40 years, with a clinical diagnosis of COPD and symptoms for at least 2 years, at least one COPD exacerbation in the previous 12 months requiring systemic steroids and/or antibiotics, current or previous smokers with a smoking history of ≥10 pack-years, forced expiratory volume in 1 second (FEV 1 ) ≤ 50% of predicted normal value and FEV 1 / vital capacity < 70% pre-dose. Exclusion Criteria: Worsening of COPD during run-in or within 4 weeks prior to visit 2 requiring hospitalisation, a course of oral and/or inhaled steroids and/or antibiotics, use of ICS within 2 weeks prior to visit 2, use of oral/parenteral glucocorticosteroids within 4 weeks prior to visit 2, a history of asthma or any significant disease/disorder which, in the opinion of the investigator, may put the patient at risk or influence results Review: Combination inhaled steroid and long-acting beta 2 -agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary Review: Combination inhaled steroid and long-acting beta 2 -agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary Review: Combination inhaled steroid and long-acting beta 2 -agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary Review: Combination inhaled steroid and long-acting beta 2 -agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary Review: Combination inhaled steroid and long-acting beta 2 -agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary Review: Combination inhaled steroid and long-acting beta 2 -agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary Review: Combination inhaled steroid and long-acting beta 2 -agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary Review: Combination inhaled steroid and long-acting beta 2 -agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary 
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